Eastern Bank’s Cytokinetics CYTK Stock Holding History

Eastern Bank’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-10	Closed	-$852	–	1116
2026 Q2	$852	Buy	+10	New	+$718	﹤0.01%	1001

Other funds holding CYTK

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return

Eastern Bank's CYTK Position: Q3 2026 in Review

Eastern Bank sold out of Cytokinetics (CYTK) in Q3 2026, closing a stake of 10 shares — an estimated $852 sold.

Eastern Bank first reported a position in CYTK in Q2 2026 and held it in 1 quarter. The position peaked at $852 in Q2 2026. 348 funds tracked by Wall St. Rank hold CYTK as of Q3 2026.

Eastern Bank reported no remaining Cytokinetics position as of Q3 2026 after selling out during the quarter.
Eastern Bank sold 10 Cytokinetics shares in Q3 2026, an estimated $852.
Eastern Bank first reported a position in Cytokinetics in Q2 2026 and held it in 1 quarter.
Eastern Bank's Cytokinetics position peaked at $852 in Q2 2026.
348 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2026.

Based on Eastern Bank's 13F filing for Q3 2026, filed 5 Oct 2026.